All In Biotech

Drug Trial Radar · NCT06175065

Safety, PK and PD Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

A Phase 2a Randomized, Doubled-Blind, Placebo-Controlled Trial to Evaluate Safety, Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Last checked: Nov 19, 2026Latest source record: May 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Jan 25, 2024

Primary completion

Jun 2025

Study completion Jun 2025

Sponsor

Lead sponsor
ReAlta Life Sciences, Inc.Industry
Sponsor type
Industry
First posted
Dec 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

AECOPD is a major cause of hospital admission and mortality. They contribute to long-term decline in lung function, physical capacity, and quality of life (QoL). RLS-0071 is a novel peptide being developed for the treatment of AECOPD. This study is designed to evaluate the safety and tolerability of RLS-0071 in the treatment of adults with moderate exacerbations of COPD.

Conditions

  • Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Interventions

  • RLS-0071Drug

    RLS-0071, will be administered as an IV infusion 10 mg/kg. Planned infusion duration is 8 minutes.

  • PlaceboDrug

    Placebo control (commercial sterile saline), will be administered as an IV infusion. Planned infusion duration is 8 minutes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-related adverse events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)Time frame: Day 1 to Day 60

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Site 02

    St. Petersburg, Florida

  • Site 03

    Glen Burnie, Maryland

  • Site 04

    Omaha, Nebraska

  • Site 01

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.